Chemical compound
 ;templatestyles src="Infobox drug/styles.css"/ ;
SEP-4199, also known as non-racemic amisulpride, is a non-racemic form of amisulpride which is under development for the treatment of bipolar depression. It is taken by mouth.
It was developed to have higher binding affinity for the serotonin 5-HT7 receptor and lower affinity for the dopamine D2 receptor compared to conventional racemic amisulpride. It contains the ("R")- and ("S")-enantiomers of amisulpride (aramisulpride and esamisulpride) in an 85:15 ratio rather than a 50:50 ratio. The modification is hoped to give the compound improved effectiveness and fewer side effects.
If approved, it would be the first form of amisulpride approved in the United States for psychiatric indications. It is in phase 3 clinical trials for bipolar depression as of December 2023. Its development was reported to have been discontinued in certain countries including the United States and Japan in November and December 2023. Sources are conflicting on whether it remains in development.
References.
 ;templatestyles src="Reflist/styles.css" / ;